MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
8.70
-0.34
-3.76%
After Hours: 8.82 +0.12 +1.38% 19:16 04/12 EDT
OPEN
9.03
PREV CLOSE
9.04
HIGH
9.19
LOW
8.61
VOLUME
267.11K
TURNOVER
0
52 WEEK HIGH
40.60
52 WEEK LOW
4.004
MARKET CAP
187.78M
P/E (TTM)
-2.1825
1D
5D
1M
3M
1Y
5Y
Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement
Benzinga · 1d ago
OUTLOOK THERAPEUTICS - FILES PROSPECTUS SUPPLEMENT RELATED TO OFFER, SALE OF UP TO $93.7 MLN OF COMMON STOCK THAT MAY BE SOLD UNDER SALES AGREEMENT
Reuters · 1d ago
GREAT POINT PARTNERS, LLC REPORTS 9.99% PASSIVE STAKE IN OUTLOOK THERAPEUTICS AS OF APRIL 1- SEC FILING
Reuters · 5d ago
Weekly Report: what happened at OTLK last week (0401-0405)?
Weekly Report · 5d ago
OUTLOOK THERAPEUTICS INC - ON APRIL 1, RECEIVED WRITTEN NOTICE FROM NASDAQ INFORMING COMPANY THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE
Reuters · 04/02 20:17
Insiders Buying Outlook Therapeutics And 2 Other Stocks
U.S. Stocks closed mixed on Thursday. There were a few notable insider trades. Insider purchases indicate confidence in the company's prospects or that they view the stock as a bargain. CION Investment Corporation and Outlook Therapeutics made notable insider purchases. Rocket Companies, Inc. Also made a notable purchase.
Benzinga · 04/01 14:46
Weekly Report: what happened at OTLK last week (0325-0329)?
Weekly Report · 04/01 12:17
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval
Outlook Therapeutics' drug ONS-5010 is being developed for the treatment of patients with wet age-related macular degeneration. The positive CHMP opinion could mean possible European Approval. European Commission expected to decide upon approval for this in the next few months. The anti-VEGF market size is projected to reach $13.54 billion by 2030.
Seeking Alpha · 03/31 13:25
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.